**Key facts**

Xultophy® is indicated for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with basal insulin do not provide adequate glycaemic control.

* Approved for use in the EU

** The maximum dose is 50 dose steps corresponding to 50 units of insulin degludec and 1.8 mg of liraglutide (One dose step = 1 unit of insulin degludec and 0.036 mg of liraglutide.)

** How it works**

Xultophy® is a combination of insulin degludec (a once-daily basal insulin that provides an ultra-long duration of action) and liraglutide (a once-daily human GLP-1 analogue), in one pen.

** Basal Insulin and GLP-1 Analogue in One Pen**

** Once-Daily Single Injection**

** Administered With or Without Meals**

** Xultophy® Is Administered in Dose Steps**

** Insulin Degludec**

- Ultra-long duration of action

** Liraglutide**

- GLP-1 Analogue
  - Stimulates insulin secretion and decreases glucagon secretion in a glucose-dependent manner

** Lowers HbA1c by Facilitating Glucose Uptake**

** Reduces HbA1c through a Reduction of FPG and PPG**

* Following the binding of insulin receptors on muscle and fat cells and simultaneous inhibition of glucose output from the liver

** FPG = Fasting Plasma Glucose; PPG = Postprandial Plasma Glucose